GSE182821
NCI-H1688 cells treated with natural compounds(sanguinarine chloride, cepharanthine and evodiamine), or (+)-JQ-1, or panobinostat, or sanguinarine chloride in combination with panobinostat or (+)-JQ-1.
Purpose: we used next generation sequencing to analyze gene expression profiles of NCI-H1688 treated with different drugs and elaborated the combinatorial effect of sanguinarine chloride and panobinostat or (+)-JQ-1.The goals of this study are to compare the drug effect and find out the resonally synergistic effects in NCI-H1688. Overall design: Human SCLC cell NCI-H1688 was cultured under standard conditions and treated for 24 hours with either DMSO, or sanguinarine(1 µM), or cepharanthine(3 µM), or evodiamine(3 µM), or (+)-JQ-1(28 µM), or panobinostat(60 nM), or sanguinarine chloride(1 µM) combine with panobinostat(60 nM), or sanguinarine chloride(1 µM) combine with (+)-JQ-1(28 µM). Total RNA was collected from each treatment group and sequencing libraries were generated using NEBNext UltraTM RNA Library Prep Kit for Illumina (NEB, USA) following manufacturer's recommendations and index codes were added to attribute sequences to each sample. RNA sequence was performed using Nova 6000 Illumina sequencing platform. The reads were mapped to the human reference genome (GRCh38) by STAR software (Version 2.5.1), annotation from GENCODE version vM21 was used. Differential gene expression was performed using DESeq2. qRT–PCR validation was performed using SYBR Green assays.